SCHEMBL277638

SCHEMBL277638

[O]c1ncc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
GPR3 P46089 1/20 0.46
EGFR P00533 1/20 0.46
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 2/20 0.44
GLA P06280 1/20 0.44
ACHE P22303 1/20 0.44
CYP1A2 P05177 5/20 0.43
HTR3A P46098 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
PDPK1 O15530 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE10A Q9Y233 1/20 0.40
MGAM O43451 2/20 0.38
NCF1 P14598 1/20 0.38
NOS2 P35228 1/20 0.38
BACE1 P56817 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1672650 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL30198446 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL30527184 0.75 CYP1A2 (0.60) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL13911016 0.71 CYP1A2 (0.56) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL3073296 0.71 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL7900625 0.71 KDM4E (0.52) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL329760 0.71 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL163312 0.71 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL17871059 0.71 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1HPGD
SCHEMBL1748568 0.71 KDM4E (0.46) KDM4EGPR3EGFRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210834-A1 RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) 2023-07-06 US claimed
WO-2021039824-A1 RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR 国立大学法人 岡山大学 2021-03-04 WO claimed
CN-101372475-A Aromatic heterocyclic substituted diphenyl urea derivative and application thereof NANJING UNIVERSITY OF TECHNOLOGY (CN) 2009-02-25 CN claimed
EP-1426361-B1 Novel composition containing a bi-cyclic compound and a glyceride SUCAMPO AG (CH) 2008-07-30 EP claimed
EP-0731095-B1 4-Alkylthio-pyrimidin-5-ylacetic acid derivatives BAYER AG (DE) 2002-07-03 EP claimed
US-6319925-B1 MICROBICIDAL, ACARICIDAL AND INSECTICIDAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 2001-11-20 US claimed
EP-0848701-B1 O-BENZYL OXIME ETHER DERIVATIVES AND THEIR USE IN CROP PROTECTION COMPOSITIONS NOVARTIS AG (CH) 2000-05-17 EP claimed
US-5776941-A FUNGICIDES SANDOZ LTD (CH) 1998-07-07 US claimed
EP-0848701-A1 O-BENZYL OXIME ETHER DERIVATIVES AND THEIR USE IN CROP PROTECTION COMPOSITIONS Novartis AG (CH) 1998-06-24 EP claimed
WO-1997001530-A1 O-BENZYL OXIME ETHER DERIVATIVES AND THEIR USE IN CROP PROTECTION COMPOSITIONS NOVARTIS AG (CH) 1997-01-16 WO claimed
CN-116323718-B Composition for photo-alignment film, and optical laminate 富士胶片株式会社 2024-07-02 CN disclosed
EP-4371979-A1 FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT Kumiai Chemical Industry Co., Ltd. (JP) 2024-05-22 EP disclosed
EP-4366733-A1 TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF LANDOS BIOPHARMA, INC. (US) 2024-05-15 EP disclosed
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 CN disclosed
WO-2024057812-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL CURED LAYER, OPTICAL FILM, POLARIZING PLATE, IMAGE DISPLAY DEVICE, MONOMER, AND COPOLYMER 富士フイルム株式会社 2024-03-21 WO disclosed
EP-0483851-A1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives Mitsubishi Chemical Corporation (JP) 1992-05-06 EP disclosed
EP-0425134-A1 Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-05-02 EP disclosed
US-4963582-A ANTHELMINTICS, ACARICIDES, INSECTICIDES SANKYO COMPANY LIMITED (JP) 1990-10-16 US disclosed
EP-0342710-A1 Macrolide compounds, their preparation and their use Sankyo Company Limited (JP) 1989-11-23 EP disclosed
EP-0246739-A2 Macrolide compounds, their preparation and their use SANKYO COMPANY LIMITED (JP) 1987-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210834-A1 RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR EMG1, TRDMT1, BCDIN3D KDM4E 1740/4885GPR3 4578/4885EGFR 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.